Trial Profile
Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of OSU6162 in the treatment of residual symptoms after stroke
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2021
Price :
$35
*
At a glance
- Drugs OSU 6162 (Primary)
- Indications Chronic fatigue syndrome; Stroke; Stroke complications
- Focus Therapeutic Use
- Sponsors Carlsson Research AB
- 30 Sep 2020 Status changed from active, no longer recruiting to completed.
- 10 Aug 2020 Planned End Date changed from 1 Mar 2022 to 1 Sep 2022.
- 10 Aug 2020 Status changed from completed to active, no longer recruiting.